Dr. James Cleary discusses the use of HER2-directed therapies for the treatment of CRC.
Colorectal
Advertisement
Dr. Ashwin Somasundaram discusses the results of a recent phase 2 study of ipilimumab, nivolumab, and panitumumab for mCRC.
CheckMate-8HW remains in progress to determine secondary end points such as overall survival.
Low-dose aspirin halved recurrence in resected PIK3CA-mutated colorectal cancer, per data from the ALASCCA trial.
Dr. Michael Foote breaks down the CheckMate 8HW trial and supports dual immunotherapy as a first-line option in dMMR CRC.
Dr. Foote discusses the BREAKWATER trial and the impact of BRAF-targeted therapy in metastatic colorectal cancer.
Sassun-Mayo N/TNM staging demonstrated superior OS stratification compared with current AJCC staging.
Dr. Eng discusses the rising global incidence of early-onset CRC, as highlighted in a recent Lancet Oncology publication.
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
The guideline was developed using a multidisciplinary team of oncologists in collaboration with ASCO and the SUO.
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
Advertisement
Roundtable Discussions
Video Insights
Advertisement
Section Editor
Michael Foote, MDMedical Oncologist | Memorial Sloan Kettering Cancer Center
Advertisement
Latest GI Oncology News
April 17, 2025
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.